{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T09:58:48Z","timestamp":1756893528548,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Theravance Biopharma, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40262-020-00918-7","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T20:04:39Z","timestamp":1598558679000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit\/Hyperactive Disorder or Fibromyalgia Pain"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8621-500X","authenticated-orcid":false,"given":"Jitendra","family":"Kanodia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7474-1328","authenticated-orcid":false,"given":"Arthur","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6236-5000","authenticated-orcid":false,"given":"R. Michael","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Bourdet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"issue":"2","key":"918_CR1","doi-asserted-by":"publisher","first-page":"pyu027","DOI":"10.1093\/ijnp\/pyu027","volume":"18","author":"JA Smith","year":"2015","unstructured":"Smith JA, Bourdet DL, Daniels OT, Ding YS, Gallezot JD, Henry S, et al. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2015;18(2):pyu027.","journal-title":"Int J Neuropsychopharmacol."},{"issue":"Suppl. 2","key":"918_CR2","first-page":"S748","volume":"33","author":"S Hegde","year":"2018","unstructured":"Hegde S, Pulido-Rios M, McNamara A, Smith J, Smith W, Kanodia J, et al. Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in subjects with primary autonomic failure [abstract]. Mov Disord. 2018;33(Suppl. 2):S748.","journal-title":"Mov Disord."},{"key":"918_CR3","doi-asserted-by":"crossref","unstructured":"Kaufmann H, Biaggioni I, Chatamra K, Panneerselvam P, Haumann B, Vickery R. A Phase 2 study of the efficacy, durability, and safety of ampreloxetine (TD-9855), a norepinephrine reuptake inhibitor, given once-daily to treat neurogenic orthostatic hypotension (nOH) in subjects with synucleinopathies. Poster presented at the International Parkinson and Movement Disorder Society; 22\u201326 September 2019; Nice.","DOI":"10.1016\/j.parkreldis.2020.06.302"},{"issue":"9","key":"918_CR4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1007\/s00415-012-6736-7","volume":"260","author":"M Metzler","year":"2013","unstructured":"Metzler M, Duerr S, Granata R, Krismer F, Robertson D, Wenning GK. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol. 2013;260(9):2212\u20139.","journal-title":"J Neurol"},{"key":"918_CR5","unstructured":"Florinef (fludrocortisone acetate) [package insert]. Bristol: Monarch Pharmaceuticals, Inc,; 2003."},{"key":"918_CR6","unstructured":"ProAmatine (midodrine) [package insert]. Lexington: Shire US Inc., 2017."},{"key":"918_CR7","unstructured":"Northera (droxidopa) [package insert]. Deerfield: Lundbeck NA Ltd., 2017."},{"issue":"12","key":"918_CR8","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00702-017-1791-y","volume":"124","author":"S Eschlb\u00f6ck","year":"2017","unstructured":"Eschlb\u00f6ck S, Wenning G, Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm (Vienna). 2017;124(12):1567\u2013605.","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"918_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/mdc3.12478","volume":"4","author":"JA Palma","year":"2017","unstructured":"Palma JA, Kaufman H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298\u2013308.","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"918_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1212\/WNL.0000000000000615","volume":"83","author":"H Kaufmann","year":"2014","unstructured":"Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328\u201335.","journal-title":"Neurology"},{"issue":"5","key":"918_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/mds.26086","volume":"30","author":"RA Hauser","year":"2015","unstructured":"Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rouse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord. 2015;30(5):646\u201354.","journal-title":"Mov Disord"},{"issue":"1","key":"918_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1161\/HYPERTENSIONAHA.114.04035","volume":"65","author":"I Biaggioni","year":"2015","unstructured":"Biaggioni I, Freeman R, Mathias CP, Low P, Hewitt LA, Kaufmann H, et al. Randomized withdrawal study of subjects with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65(1):101\u20137.","journal-title":"Hypertension"},{"issue":"1","key":"918_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1161\/HYPERTENSIONAHA.107.089961","volume":"50","author":"C Shibao","year":"2007","unstructured":"Shibao C, Raj SR, Gamoa A, Diedrich A, Choi L, Black BK, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007;50(1):47\u201353.","journal-title":"Hypertension"},{"key":"918_CR14","unstructured":"Strattera (atomoxetine hydrochloride) [package insert]. Indianapolis: Eli Lilly and Company; 2017."},{"key":"918_CR15","doi-asserted-by":"crossref","unstructured":"Yeola S, Bolleddula J, Brassil P, Worboys P, Bourdet D. Absorption, metabolism, and excretion of [14C]TD-9855 after single oral administration to healthy human subjects. Poster presented at the American Association of Pharmaceutical Scientists; 13\u201317 November 2016; Denver (CO).","DOI":"10.26226\/morressier.57d6b2bed462b8028d88e597"},{"key":"918_CR16","volume-title":"Declaration of Helsinki: recommendations guiding doctors in clinical research","author":"World Medical Association","year":"1964","unstructured":"World Medical Association. Declaration of Helsinki: recommendations guiding doctors in clinical research. Ferney-Voltaire: World Medical Association; 1964."},{"key":"918_CR17","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Assessing the effect of food and drugs in INDs and NDAs: clinical pharamacology considerations. Guidance for industry. February 2019. Available from: https:\/\/www.fda.gov\/media\/121313\/download. Accessed 15 June 2020."},{"key":"918_CR18","volume-title":"The adult ADHD Clinical Diagnostic Scale (ACDS)","author":"L Adler","year":"2004","unstructured":"Adler L, Spencer T. The adult ADHD Clinical Diagnostic Scale (ACDS). New York: New York University School of Medicine; 2004."},{"issue":"4","key":"918_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/clpt.2013.254","volume":"95","author":"KR Crews","year":"2014","unstructured":"Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"918_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/art.1780330203","volume":"33","author":"F Wolfe","year":"1990","unstructured":"Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160\u201372.","journal-title":"Arthritis Rheum"},{"key":"918_CR21","first-page":"419","volume":"7","author":"K Srivastava","year":"2013","unstructured":"Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adher. 2013;7:419\u201334.","journal-title":"Patient Prefer Adher"},{"issue":"3","key":"918_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x","volume":"97","author":"MS Faber","year":"2005","unstructured":"Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, when? Basic Clin Pharmacol Toxicol. 2005;97(3):125\u201334.","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00918-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00918-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00918-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T23:55:54Z","timestamp":1630022154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00918-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00918-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"27 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Theravance Biopharma, Inc. Kirsty Nahm MD of The Curry Rockefeller Group, LLC provided assistance with writing\/formatting\/proofreading\/collation of the author comments and this assistance was funded by Theravance Biopharma, Inc. Open access publication of this manuscript was sponsored by Theravance Biopharma, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jitendra Kanodia, Arthur Lo, R. Michael Baldwin, Richard A. Graham, and David L. Bourdet are current or former employees of Theravance Biopharma US, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Theravance Biopharma, Inc. (and its affiliates) will not be sharing individual de-identified participant data or other relevant study documents.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}